Galapagos NV moved a step closer towards the market as its lead product, filgotinib, for rheumatoid arthritis (RA) successfully completed a Phase 3 trial, and two other late-stage studies of the same drug neared the finishing line. ---Subscribe to MedNous to access this article--- Company News
